Skip to content

Inspection Record

Bausch and Lomb, Inc — FDA 483 Findings

US FDAInspected 2015-07-24Published 2024-01-17 17 findingsStability and storageOther quality systemLaboratory and QC controlsProcess validationRegulatory reporting and change controlTraining and personnelEquipment and facilityDeviation, CAPA, and investigationComplaint and recall handling

View the regulator's official source The source document is always the basis for judgement.

Findings

1Stability and storage

0 P rocedures for controlling the storage of product in storage areas and stock rooms were not implemented to prevent mix-ups, damage, other adverse effects .

2Other quality system

The design plan does not describe the design and development activities, define responsibilities for implementation of design and development activities, and identify and describe the interfaces with other groups or activities as appropriate.

3Laboratory and QC controls

Specifically, The current analytical test methods for OTC drug products are not stability-indicating to demonstrate levels of degradation or other impurities that may exist in such products .

4Other quality system

A correction or removal, co nducted to reduce a risk to health posed by a device, was not reported in writing to FDA.

5Process validation

There are no written procedures for production and process controls designed to ensure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess .

6Regulatory reporting and change control

An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a market dev ice may have cause or contributed to a death or serious injury.

7Other quality system

Appropriate procedures have not been defined and documented for controlling environmental conditions.

8Training and personnel

Employees are not given training in the particular operations they perf orm as part of their function.

9Equipment and facility

Procedures have not been documented to prevent contaminations of equipment or product by certain substances.

10Other quality system

Quality audits were not c onducted to verify that the quality system is effective in fulfilling your quality system objectives.

11Deviation, CAPA, and investigation

A validated process was not revalidated when changes or process deviations occurred.

12Complaint and recall handling

Complaints involving the possible failure of a device to meet any of its specifications were not investigated where necessary .

13Equipment and facility

Written procedures are not follo wed for the cleaning and maint enance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product .

14Equipment and facility

Proce dures have not been followed to prevent contamination of equipment or product by certain substances.

15Other quality system

2 Procedure s have not been implemented to ensure that mix-ups, damage, or other adverse effects to product do not occur during handling .

16Other quality system

Design reviews wer e not p erformed at ap propriate times, following the review schedule.

17Stability and storage

Procedures for controlling the storage of product in s torage areas and stock rooms were not established to prevent mix-ups, damage, other adverse effects.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Bausch and Lomb, Inc company profile — full historyAll US FDA findings US FDA documents, 2024 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.